Company intelligence / Profile preview

Firalis

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Firalis specializes in multi‑omics biomarker discovery, validation, and regulatory qualification across the drug development pipeline. The company provides end-to-end services from early discovery through clinical phases to post-market surveillance. Its proprietary platforms focus on long non-coding RNA-based diagnostics for cardiology and neurology. Notably, its FIMICS panel has been clinically validated to predict outcomes such as COVID‑19 mortality with high accuracy. The company also develops CE-marked IVD kits.[1][2][3][5]

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Multi-omics biomarkers (genomics, proteomics, transcriptomics)Long non-coding RNAs (lncRNAs)ELISA kitsRecombinant proteinsMonoclonal antibodies
Industry: Molecular Diagnostics

Partnerships

Collaborates with academic institutions and biopharma companies on biomarker R&D programs; involved in EU H2020 FastTrack COVIRNA project for COVID‑19 outcome prediction using their technology.[1][3]

Beyond the preview

Go deeper on Firalis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Firalis.

Explore the full profile